PUBLICATION IN VACCINES OF A NEW ARTICLE DESCRIBING THE CAPABILITY OF OUR ENGINEERED PDC*LINE VACCINE TO PRIME & EXPAND MULTISPECIFIC ANTIGEN-SPECIFIC T-CELLS
We are very pleased to announce the publication in Vaccines of a new article describing the capability of our Engineered PDC*line Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-Cells! Congratulations and thank's to our R&D team and our partner Etablissement Français du Sang (February 12th, 202).
Abstract: Because dendritic cells are crucial to prime and expand antigen-specific CD8+ T-cells, several strategies are designed to use them in therapeutic vaccines against infectious diseases or cancer. In this context, off-the-shelf allogeneic dendritic cell-based platforms are more attractive than individualized autologous vaccines tailored to each patient. In the present study, a unique dendritic cell line (PDC*line) platform of plasmacytoid origin, already used to prime and expand antitumor immunity in melanoma patients, was improved thanks to retroviral engineering. We demonstrated that the clinical-grade PDC*line, transduced with genes encoding viral or tumoral whole proteins, efficiently processed and stably presented the transduced antigens in different human leukocyte antigen (HLA) class I contexts. Moreover, the use of polyepitope constructs allowed the presentation of immunogenic peptides and the expansion of specific cytotoxic effectors. We also demonstrated that the addition of the Lysosome-associated membrane protein-1 (LAMP-1) sequence greatly improved the presentation of some peptides. Lastly, thanks to transduction of new HLA molecules, the PDC platform can benefit many patients through the easy addition of matched HLA-I molecules. The demonstration of the effective retroviral transduction of PDC*line cells strengthens and broadens the scope of the PDC*line platform, which can be used in adoptive or active immunotherapy for the treatment of infectious diseases or cancer.
Get access to full article in PDF format below: